LNPs have been widelyemployed for the delivery of diverse types of nucleic acid therapeutics(e.g., mRNA, siRNA, DNA).19,20 Their capacity to efficientlypackage and facilitate the cytosolic delivery of drug cargo is vitalto the success of several FDA-approved LNP-based nanomedicines, includingthe Moderna and Pfizer-BioNTech mRNA COVID-19 vaccines.21 However, LNP formulations of 3pRNA have notyet been explored for the immunotherapeutic activation of RIG-I. The gene discussed is RIGI; the disease is COVID-19.